Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of Monday, August 3, 2026.
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 23andMe Holding Co. (ME) | $15.31M | N/A | N/A | N/A | N/A |
| NRC Health (NRC)vs › | $439.69M | 77.30 | 30.78 | 25.79 | 27.53 |
| Shoulder Innovations, Inc. (SI)vs › | $471.59M | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.22B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.64B | 17.51 | 40.63 | 513.84 | 513.84 |
| DENTSPLY SIRONA Inc. (XRAY)vs › | $2.68B | N/A | 23.81 | 50.79 | 57.43 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.19B | N/A | 61.96 | 88.48 | 88.48 |
| Tempus AI, Inc. (TEM)vs › | $7.69B | N/A | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.09B | N/A | 60.92 | 60.92 | 60.92 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $8.80B | 53.62 | 28.63 | 28.63 | 16.20 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.61
Forward EPS (Est.)
$-10.64
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
